Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points

Lantern Pharma Inc.

Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.
FY2021 net loss $12.4M ($1.13/share) vs $5.9M ($1.37/share) in FY2020; R&D expense rose to $7.6M.
RADR AI platform grew from 1.2B to over 18B data points during 2021; target of 25B by end 2022.
LP-300 Phase 2 Harmonic trial for never-smoker NSCLC expected to launch in 2022; LP-184 multiple Phase 1 trials in 2022.
LP-184 received Orphan Drug Designations for pancreatic cancer, GBM, ATRT; Rare Pediatric Disease Designation for ATRT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.